NovaBay's first commercial deal for NeutroPhase targets China
This article was originally published in Scrip
In a sign of the continued rise of China as a priority target for both Big Pharma and development stage companies alike, NovaBay Pharmaceuticals' first commercial partnership for its lead product, the wound healing preparation NeutroPhase (pure hypochlorous acid), is with the Shanghai-based firm Pioneer Pharma.
You may also be interested in...
The alliance between China’s largest insurance group and Shionogi takes concrete shape as investment plans and new Asia companies move ahead, marking a major technology and geographic pivot for the Japanese pharma firm.
More progress for partners’ amyloid-targeting antibody portfolio as they look to demonstrate benefit of early intervention in pre-symptomatic disease in new collaborative Phase III trial.
Join us for a quick audio roundup of five useful things to know from Scrip's recent coverage of the global biopharmaceutical industry.